Identification of SARS-CoV-2 inhibitors using lung and colonic organoids
폐 및 결장 오르가노이드를 이용한 SARS-CoV-2 억제제 식별
Article
[키워드] ACE2
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
alveolar
approved
Cell
cell types
cells
chemokine
chemokines
colonic
complementary
coronavirus
COVID-19
COVID-19 therapeutics
Disease model
disease models
drug
Drug administration
Drug screening
enterocytes
Entry inhibitor
entry inhibitors
Express
facilitate
FDA
food
hPSC-derived colonic organoid
human disease
identification
identify
Imatinib
infect
inhibited
inhibitor
lung
Manifestations
mycophenolic acid
Organoid
outcome
Patient
patients with COVID-19
performed
pluripotent stem cell
quinacrine
respiratory
respiratory tract
robust
SARS-CoV-2
SARS-COV-2 infection
severe acute respiratory syndrome Coronavirus
significantly
stem cells
These data
US Food and Drug Administration
valuable resource
[DOI] 10.1038/s41586-020-2901-9 PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41586-020-2901-9 PMC 바로가기 [Article Type] Article